SmithKline Beecham
Executive Summary
Jerry Karabelas becomes VP-marketing of the company's U.S. prescription drug business effective June 27. Karabelas originally joined SmithKline in 1982, eventually becoming a group VP for gastrointestinal products. He left the firm in December 1989 to become CEO of Cellular Transplants Inc., a Providence, Rhode Island-based biotech firm. In his new position at SmithKline Beecham, Karabelas will replace Roger Ross, a 25-year SmithKline veteran who has decided to leave the company. The VP-marketing position currently reports to Fred Kyle, who heads U.S. pharmaceutical operations. However, the company is seeking a replacement for Kyle, who was recently given overall responsibility for worldwide manufacturing.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.